CRIS

Company Overview — What Does CURIS INC Do?

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts. CURIS INC (CRIS) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO James E. Dentzer and employs approximately 60 people, headquartered in LEXINGTON, Massachusetts. With a market capitalization of $21M, CRIS is one of the notable companies in the Healthcare sector.

CURIS INC (CRIS) Stock Rating — Avoid (April 2026)

As of April 2026, CURIS INC receives a Avoid rating with a composite score of 19.7/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.CRIS ranks #4,336 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, CURIS INC ranks #792 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CRIS Stock Price and 52-Week Range

CURIS INC (CRIS) currently trades at $0.48. The stock lost $0.03 (6.1%) in the most recent trading session. The 52-week high for CRIS is $3.13, which means the stock is currently trading -84.7% from its annual peak. The 52-week low is $0.77, putting the stock -37.9% above its annual trough. Recent trading volume was 1.9M shares, reflecting moderate market activity.

Is CRIS Overvalued or Undervalued? — Valuation Analysis

CURIS INC (CRIS) carries a value factor score of 17/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.02x, versus the sector average of 2.75x. The price-to-sales ratio is 1.96x, compared to 1.66x for the average Healthcare stock.

At current multiples, CURIS INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

CURIS INC Profitability — ROE, Margins, and Quality Score

CURIS INC (CRIS) earns a quality factor score of 15/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -678.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -185.5% versus the sector average of -33.1%.

On a margin basis, CURIS INC reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -326.4% (sector: -66.1%). Net profit margin stands at -336.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 24.7% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CRIS Debt, Balance Sheet, and Financial Health

CURIS INC has a debt-to-equity ratio of 266.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 0.49x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $7M. Cash and equivalents stand at $9M.

CRIS has a beta of 1.28, meaning it is more volatile than the broader market — a $10,000 investment in CRIS would be expected to move 28.2% more than the S&P 500 on any given day. The stability factor score for CURIS INC is 23/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

CURIS INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, CURIS INC reported revenue of $11M and earnings per share (EPS) of $-0.58. Net income for the quarter was $-37M. Gross margin was 100.0%. Operating income came in at $-36M.

In FY 2025, CURIS INC reported revenue of $9M and earnings per share (EPS) of $-0.58. Net income for the quarter was $-8M. Revenue grew -13.4% year-over-year compared to FY 2024. Operating income came in at $-6M.

In Q3 2025, CURIS INC reported revenue of $3M and earnings per share (EPS) of $-0.49. Net income for the quarter was $-8M. Revenue grew 8.4% year-over-year compared to Q3 2024. Operating income came in at $-7M.

In Q2 2025, CURIS INC reported revenue of $3M and earnings per share (EPS) of $-0.68. Net income for the quarter was $-9M. Revenue grew 8.0% year-over-year compared to Q2 2024. Operating income came in at $-8M.

Over the past 8 quarters, CURIS INC has demonstrated a growth trajectory, with revenue expanding from $3M to $11M. Investors analyzing CRIS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CRIS Dividend Yield and Income Analysis

CURIS INC (CRIS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CRIS Momentum and Technical Analysis Profile

CURIS INC (CRIS) has a momentum factor score of 11/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 52/100 reflects moderate short selling activity.

CRIS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, CURIS INC (CRIS) ranks #792 out of 838 stocks based on the Blank Capital composite score. This places CRIS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CRIS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CRIS vs S&P 500 (SPY) comparison to assess how CURIS INC stacks up against the broader market across all factor dimensions.

CRIS Next Earnings Date

No upcoming earnings date has been announced for CURIS INC (CRIS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CRIS? — Investment Thesis Summary

The quantitative profile for CURIS INC suggests caution. The quality score of 15/100 flags below-average profitability. The value score of 17/100 indicates premium valuation. Momentum is weak at 11/100, a headwind for near-term performance. High volatility (stability score 23/100) increases portfolio risk.

In summary, CURIS INC (CRIS) earns a Avoid rating with a composite score of 19.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CRIS stock.

Related Resources for CRIS Investors

Explore more research and tools: CRIS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CRIS head-to-head with peers: CRIS vs AZN, CRIS vs SLGL, CRIS vs VMD.